Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Impaired protein aggregate handling and clearance underlie the pathogenesis of p97/VCP-associated disease. Ju JS, Miller SE, Hanson PI, Weihl CC. The Journal of biological chemistry. 2008 283:30289-99.
Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph disease. Nascimento-Ferreira I, Santos-Ferreira T, Sousa-Ferreira L, Auregan G, Onofre I, Alves S, Dufour N, Colomer Gould VF, Koeppen A, Dglon N, Pereira de Almeida L. Brain : a journal of neurology. 2011 134:1400-15.
SQSTM1 Antibody, A170 Antibody, ORCA Antibody, OSIL Antibody, Paget disease of bone 3 Antibody, p60 Antibody, p62 Antibody, PDB3 Antibody, Sequestosome-1 Antibody, Ubiquitin-binding protein p62 Antibody, Oxidative stress induced like Antibody, p62B Antibody, ZIP3 Antibody, Sequestosome 1 Antibody, EBI3-associated protein p60 Antibody, EBIAP Antibody
Autophagy receptor that interacts directly with both the cargo to become degraded and an autophagy modifier of the MAP1 LC3 family. Required both for the formation and autophagic degradation of polyubiquitin-containing bodies, called ALIS (aggresome-like induced structures) and links ALIS to the autophagic machinery. Involved in midbody ring degradation. May regulate the activation of NFKB1 by TNF-alpha, nerve growth factor (NGF) and interleukin-1.
Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.
Immunofluorescence staining of Autophagy SQSTM1 (p62) Antibody on Methanol-fixed and PFA fixed HeLa cells. Data courtesy of Dr. Eeva-Liisa Eskelinen, University of Helsinki,Finland.
Fluorescent image of U251 cells stained with SQSTM1 (p62) antibody. U251 cells were treated with Chloroquine (50 mu M,16h), then fixed with 4% PFA (20 min), permeabilized with Triton X-100 (0.2%, 30 min). Cells were then incubated SQSTM1 (p62) primary antibody (1:200, 2 h at room temperature). For secondary antibody, Alexa Fluor 488 conjugated donkey anti-rabbit antibody (green) was used (1:1000, 1h). Nuclei were counterstained with Hoechst 33342 (blue) (10 ug/ml, 5 min). SQSTM1 (p62) immunoreactivity is localized to autophagic vacuoles in the cytoplasm of U251 cells, supported by Human Protein Atlas Data (http://www.proteinatlas.org/ENSG00000161011).
Western blot of SQSTM1 (arrow) using rabbit polyclonal Autophagy SQSTM1 (p62) Antibody (C-term ). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the SQSTM1 gene (Lane 2) (Origene Technologies).
Western blot of SQSTM1 Antibody (C331) antibody pre-incubated without(lane 1) and with(lane 2) blocking peptide in MCF-7 cell line lysate. SQSTM1 Antibody (C331) (arrow) was detected using the purified antibody.